Drugs in Dev. Infections and Infectious Diseases
Phase I/ Phase II
Japan 
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daiichi Sankyo Announces Development Progress of mRNA COVID19 Vaccine (DS-5670) in Japan
Details : Results from the trial presented no significant safety concerns. The neutralizing antibody titers 14 days after the second vaccination of DS-5670 have demonstrated acquirement of adequate immunity.
Product Name : DS-5670
Product Type : Vaccine
Upfront Cash : Inapplicable
May 26, 2022
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 24-Valent Streptococcus Pneumoniae Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Affinivax
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the parties’ new agreement, the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’s next generation pneumococcal vaccine products designed to treat Streptococcus ...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : $65.0 million
February 28, 2022
Lead Product(s) : 24-Valent Streptococcus Pneumoniae Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Affinivax
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DS-5670, an mRNA vaccine against COVID-19 using a novel nucleic acid delivery technology in phase 1/2/3 study evaluate safety and efficacy in healthy Japanese adults who completed initial vaccination also induced neutralizing activities against Omicron v...
Product Name : DS-5670
Product Type : Vaccine
Upfront Cash : Inapplicable
January 31, 2022
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPC-167832,Bedaquiline,Delamanid
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $17.8 million
Deal Type : Funding
Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-TB Combo
Details : The grant will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in combination with its delamanid and Johnson & Johnson’s bedaquiline, for patients with drug-susceptible pulmonary tuberculosis (DS-TB).
Product Name : OPC-167832
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 08, 2021
Lead Product(s) : OPC-167832,Bedaquiline,Delamanid
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Bill & Melinda Gates Foundation
Deal Size : $17.8 million
Deal Type : Funding
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Daiichi Sankyo Initiates Phase 1/2 Clinical Trial for mRNA COVID19 vaccine in Japan
Details : The phase 1/2 trial is being conducted in Japan in a total of 152 healthy adults, including elderly individuals, to evaluate the safety and immunogenicity of the vaccine and thereby estimate the recommended dose of DS-5670.
Product Name : DS-5670
Product Type : Vaccine
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : DS-5670
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NVX-COV2373
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Takeda completed enrollment in the company’s Phase 1/2 immunogenicity and safety study of Moderna’s COVID-19 vaccine...
Product Name : NVX-COV2373
Product Type : Vaccine
Upfront Cash : Inapplicable
February 24, 2021
Lead Product(s) : NVX-COV2373
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First participant has been dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd. TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine cand...
Product Name : TAK-919
Product Type : Vaccine
Upfront Cash : Inapplicable
January 21, 2021
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Moderna Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
